Highlights
- Integral Diagnostics (ASX:IDX) reported FY26 Revenue and other income of AUD 788.7 million.
- Operating EBITDA was AUD 164.8 million, with a 20.9% margin.
- Operating net profit after tax reached AUD 47.4 million.
- The final fully Franked Dividend was 6.0 cents per share.
Integral Diagnostics Limited provides medical imaging and diagnostic services across Australia and New Zealand, using radiology practices to support diagnosis and treatment decisions. Shares in Integral Diagnostics (ASX:IDX) were trading at AUD 1.638 on November 17, 2026, a decline of 0.76% for the session. The company’s FY26 results and October Annual General Meeting materials outlined revenue growth, a higher operating Margin and the ongoing effects of integrating the Capitol Health business.
Imaging Network and Patient Services
Integral Diagnostics (ASX:IDX) operates diagnostic imaging services, including radiology and other modalities requested by referring clinicians. During FY26 its Australian operations covered Queensland, South Australia, Tasmania, Victoria, New South Wales and Western Australia, alongside its New Zealand presence. The Business depends on radiologists, technical staff, imaging equipment, referral volumes and operational coordination across locations. Investment in equipment and clinic capacity is therefore relevant to both patient access and the recurring cost structure of the network.
Integration and 2026 Operational Developments
The company’s financial reports identify the integration of Capitol Health as an important contributor to its group structure and financial comparisons. Integral Diagnostics (ASX:IDX) continues to account for transaction, restructuring and integration items separately from its operating Earnings measures. At its October 2026 annual general meeting, management reiterated the reported improvements in revenue, operating EBITDA, margins and earnings. Consolidating reporting and service delivery across an enlarged network remains an operational task, and financial statements continue to disclose the related costs.
FY26 Revenue and Profitability
For the financial year ended June 30, 2026, Integral Diagnostics (ASX:IDX) reported AUD 788.7 million of revenue and other income. Operating EBITDA reached AUD 164.8 million, while the corresponding Operating Margin was 20.9%. Operating net profit after tax was AUD 47.4 million, and statutory net profit after tax was AUD 22.0 million. The difference between these profit measures reflects disclosed non-operating adjustments, including transaction and integration costs. Operating Diluted Earnings per Share were 12.6 cents. These measures provide distinct views of operating activity and the final statutory outcome.
Cash Flow, Leverage and Distributions
Integral Diagnostics (ASX:IDX) generated AUD 106.4 million in operating free Cash Flow during FY26. The company reported cash flow conversion of 82.0% before replacement Capital Expenditure under its disclosed measure. Net Debt to operating EBITDA stood at 2.3 times at June 30, 2026. The board declared a fully franked final dividend of 6.0 cents per share, bringing total FY26 dividends to 9.3 cents. Funding requirements for equipment, operating facilities and debt servicing remain relevant alongside Shareholder distributions.
Sector Conditions and Execution Risks
Diagnostic imaging activity is influenced by referral trends, staffing availability, reimbursement rules, equipment costs and patient demand. Integral Diagnostics (ASX:IDX) also faces integration complexity as operating systems and processes are aligned across acquired businesses. The gap between operating and statutory earnings shows that transaction-related expenditure remained material in FY26. Changes in cash conversion, replacement capital expenditure or financing costs could alter the amount of cash available for debt reduction and distributions.
Key Insights
Integral Diagnostics (ASX:IDX) reported FY26 operating EBITDA of AUD 164.8 million and statutory net profit after tax of AUD 22.0 million. The reported results combine a larger imaging network with continuing integration expenditure. Subsequent financial statements can be assessed for operating margins, cash flow, leverage and the pace at which non-operating costs change.





_11_19_2026_18_29_00_678569.jpg)
Please wait processing your request...